m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05832
 [1]
m6A modification TRHDE-AS1 TRHDE-AS1 METTL14 Methylation : m6A sites Direct Inhibition Non-coding RNA TRHDE-AS1 Regulated Target  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target TRHDE antisense RNA 1 (TRHDE-AS1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator TRHDE antisense RNA 1 (TRHDE-AS1) LncRNA View Details
Crosstalk Relationship m6A  →  ncRNA Inhibition
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary METTL14 was upstream of TRHDE antisense RNA 1 (TRHDE-AS1) to induce m6A modification of TRHDE-AS1 in PC cells. Collectively, our results show that propofol prevents PC progression by upregulating TRHDE-AS1 expression and METTL14 is involved in the m6A modification of TRHDE-AS1. These findings suggest that TRHDE-AS1 may be a potential therapeutic target for the improvement of propofol's therapeutic effect.
Responsed Disease Prostate cancer ICD-11: 2C82
 Disease Info 
Responsed Drug Propofol
 Drug Info 
Cell Process Cell proliferation
Cell migration
Cell apoptosis
In-vitro Model
 RWPE-1 Normal Homo sapiens CVCL_3791
22Rv1 Prostate carcinoma Homo sapiens CVCL_1045
DU145 Prostate carcinoma Homo sapiens CVCL_0105
LNCaP Prostate carcinoma Homo sapiens CVCL_0395
In-vivo Model DU145 cells (1 × 106 cells) with or without 200-μM propofol treatment were subcutaneously implanted into the right flank of each mouse.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2C82: Prostate cancer 1 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name CC-94676 Phase 1 [2]
External Link
TTD: DNY63Z
References
Ref 1 Propofol attenuates prostate cancer progression by upregulating TRHDE-AS1 expression, and METTL14 could mediate its m6A modification. Clin Exp Pharmacol Physiol. 2024 Nov;51(11):e13924. doi: 10.1111/1440-1681.13924.
Ref 2 ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.